Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 4/2000

Open Access 01-08-2000 | Research article

Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE

Authors: Stacey L Tannheimer, Alnawaz Rehemtulla, Stephen P Ethier

Published in: Breast Cancer Research | Issue 4/2000

Login to get access

Statement of findings

The fibroblast growth factor receptor (FGFR)2 gene has been shown to be amplified in 5-10% of breast cancer patients. A breast cancer cell line developed in our laboratory, SUM-52PE, was shown to have a 12-fold amplification of the FGFR2 gene, and FGFR2 message was found to be overexpressed 40-fold in SUM-52PE cells as compared with normal human mammary epithelial (HME) cells. Both human breast cancer (HBC) cell lines and HME cells expressed two FGFR2 isoforms, whereas SUM-52PE cells overexpressed those two isoforms, as well as several unique FGFR2 polypeptides. SUM-52PE cells expressed exclusively FGFR2-IIIb isoforms, which are high-affinity receptors for fibroblast growth factor (FGF)-1 and FGF-7. Differences were identified in the expression of the extracellular Ig-like domains, acid box and carboxyl termini, and several variants not previously reported were isolated from these cells.
Literature
1.
Johnson D, Lu J, Chen H, Werner S, Williams L: The human fibroblast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain. Mol Cell Biol. 1991, 11: 4627-4634.CrossRefPubMedPubMedCentral
2.
Champion-Arnaud P, Ronsin C, Gilbert E, Gesnel MC, Houssaint E, Breathnach R: Multiple mRNAs code for proteins related to the BEK fibroblast growth factor receptor. Oncogene. 1991, 6: 979-987.PubMed
3.
Miki T, Bottaro D, Fleming T, et al: Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci USA . 1992, 89: 246-250.CrossRefPubMedPubMedCentral
4.
Itoh K, Hattori Y, Sakamoto H: Preferential alternative splicing in cancer generates a K-sam messenger RNA with higher transforming activity. Cancer Res. 1994, 54: 3237-3241.PubMed
5.
Adnane J, Gaudray P, Dionne CA: BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene. 1991, 6: 659-663.PubMed
6.
Penault-Llorca F, Bertucci F, Adelaide J: Expression of FGF and FGF receptor genes in human breast cancer. Int J Cancer. 1991, 61: 170-176.CrossRef
7.
Kononen J, Heisdanen M, Barlund M: Biochip technologies for rapid analysis of gene amplifications in cancer [abstract]. Proc Am Assoc Cancer Res. 1999, 40: 319-
8.
McLeskey SW, Ding I, Lippman ME, Kern FG: MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor receptors and are growth-inhibited by FGF ligands. Cancer Res. 1994, 54: 523-530.PubMed
9.
Lorenzi MV, Castagnino P, Chen Q, Chedid M, Miki T: Ligand-independent activation of fibroblast growth factor receptor-2 by carboxyl terminal alterations. Oncogene. 1997, 15: 817-826. 10.1038/sj/onc/1201242.CrossRefPubMed
10.
Ethier SP, Kokeny K, Ridings J, Dilts C: erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line. Cancer Res. 1996, 56: 899-907.PubMed
11.
Ignatoski KMW, Ethier SP: Constitutive activation of pp125fak in newly isolated human breast cancer cell lines. Breast Cancer Res Treat. 1999, 54: 173-182. 10.1023/A:1006135331912.CrossRefPubMed
12.
Ignatoski KMW, Maehama T, Markwart SM, Dixon JE, Livant DL, Ethier SP: ERBB-2 overexpression confers PI 3 ' -kinase-dependent invasion capacity on human mammary epithelial cells. Br J Cancer. 2000, 82: 666-674. 10.1054/bjoc.1999.0979.CrossRefPubMedPubMedCentral
13.
Maquire H, Greene M: The new (c-erbB-2) oncogene. Semin Oncol. 1989, 16: 148-155.
14.
Forozan F, Veldman R, Ammerman CA, et al: Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer. 1999, 81: 1328-1334. 10.1038/sj.bjc.6695007.CrossRefPubMedPubMedCentral
15.
Gospodarowicz D, Neufeld G, Schweiger L: Molecular and biological characterization of FGF, an angiogenic factor which also controls proliferation and differentiation of mesoderm and ectoderm derived cells. Cell Differ. 1986, 19: 1-17. 10.1016/0045-6039(86)90021-7.CrossRefPubMed
16.
Burgess W, Maciag T: The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem. 1989, 58: 575-606. 10.1146/annurev.bi.58.070189.003043.CrossRefPubMed
17.
Johnson DE, Williams LT: Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res. 1992, 60: 1-41.CrossRef
18.
Morrison R, Sharma A, DeVellis J, Bradshaw R: Basic FGF supports the survival of cerebral cortical neurons in primary culture. Proc Natl Acad Sci USA. 1986, 83: 7537-7541.CrossRefPubMedPubMedCentral
19.
20.
Yamaguchi T, Rassant J: Fibroblast growth factors in mammalian development. Curr Opin Genet Dev. 1995, 5: 485-491.CrossRefPubMed
21.
Vlodavsky I, Miao H-Q, Medalion B, Danagher P, Ron D: Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Met Rev. 1996, 15: 177-186.CrossRef
22.
Shi E, Kan M, Xu J, Wang F, Hou J, McKeehan W: Control of fibroblast growth factor receptor kinase signal transduction by heterodimerization of combinatorial splice variants. Mol Cell Biol. 1993, 13: 3907-3918.CrossRefPubMedPubMedCentral
23.
Bellot F, Crumley G, Kaplow JM, Schlessinger J, Jaye M, Dionne CA: Ligand-induced transphosphorylation between different FGF receptors. EMBO J. 1991, 10: 2849-2854.PubMedPubMedCentral
24.
Luqmani YA, Graham M, Coombes RC: Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast and comparison with other normal tissues. Br J Cancer. 1992, 66: 273-280.CrossRefPubMedPubMedCentral
25.
Carstens RP, Eaton JV, Krigman HR, Walther PJ, Garcia-Blanco MA: Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene. 1997, 15: 3059-3065. 10.1038/sj/onc/1201498.CrossRefPubMed
26.
Dell KR, Williams LT: A novel form of fibroblast growth factor receptor 2. J Biol Chem. 1992, 267: 21225-21229.PubMed
27.
Crumley G, Bellot F, Kaplow JM, Schlessinger J, Jaye M, Dionne CA: High-affinity binding and activation of a truncated FGF receptor by both aFGF and bFGF. Oncogene. 1991, 6: 2255-2262.PubMed
28.
Pierce JH, Arnstein P, DiMarco E, et al: Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene . 1991, 6: 1189-1194.PubMed
29.
Zeillinger R, Kury F, Czerwenka K: HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene. 1989, 4: 109-114.PubMed
Metadata
Title
Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE
Authors
Stacey L Tannheimer
Alnawaz Rehemtulla
Stephen P Ethier
Publication date
01-08-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 4/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr73

Other articles of this Issue 4/2000

Breast Cancer Research 4/2000 Go to the issue

Commentary

New hurdles for translational research

Review

Future possibilities in the prevention of breast cancer: Breast cancer prevention trials

Commentary

Mammographic screening and mammographic patterns

Research article

BRCA1 and BRCA2 mutations in central and southern Italian patients

Review

Future possibilities in the prevention of breast cancer: Fat and fiber and breast cancer research

Commentary

Utilization of human tissue in breast cancer research
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits